Parabilis Medicines (NASDAQ:PBLS) Now Covered by Analysts at Leerink Partners

Leerink Partners started coverage on shares of Parabilis Medicines (NASDAQ:PBLS) in a research note issued to investors on Monday morning, MarketBeat reports. The brokerage issued an outperform rating and a $40.00 target price on the stock.

PBLS has been the subject of a number of other research reports. Wall Street Zen raised shares of Parabilis Medicines to a “hold” rating in a report on Saturday, June 20th. Guggenheim began coverage on shares of Parabilis Medicines in a research report on Monday. They set a “buy” rating and a $40.00 price objective for the company. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Parabilis Medicines currently has an average rating of “Buy” and an average price target of $41.67.

Parabilis Medicines Stock Up 0.3%

Shares of PBLS stock opened at $29.30 on Monday. Parabilis Medicines has a fifty-two week low of $24.51 and a fifty-two week high of $34.47.

Insiders Place Their Bets

In other news, Director Alan Sebulsky bought 9,065 shares of the stock in a transaction on Monday, June 15th. The stock was acquired at an average price of $26.49 per share, with a total value of $240,131.85. Following the acquisition, the director directly owned 30,000 shares in the company, valued at approximately $794,700. This trade represents a 43.30% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Guy Levy bought 500,000 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was purchased at an average price of $20.00 per share, with a total value of $10,000,000.00. Following the completion of the transaction, the insider directly owned 1,027,000 shares of the company’s stock, valued at approximately $20,540,000. The trade was a 94.88% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 530,000 shares of company stock worth $10,723,528 in the last 90 days.